Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Restaurant
|
| gptkbp:activeDuring |
gptkb:Darbepoetin_alfa
|
| gptkbp:administrativeDivision |
Once every 1 to 4 weeks
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Aranesp
|
| gptkbp:chemicalFormula |
C210H244N38O45S
|
| gptkbp:clinicalTrials |
Phase III
Improvement of quality of life in anemic patients Management of anemia Management of anemia in chronic kidney disease Prevention of transfusions Supportive care in cancer treatment |
| gptkbp:contraindication |
Hypersensitivity to darbepoetin alfa
Pure red cell aplasia Uncontrolled hypertension |
| gptkbp:developedBy |
gptkb:Amgen
|
| gptkbp:dosageForm |
Solution for injection
|
| gptkbp:drugInterdiction |
Increases red blood cell production
Longer half-life than epoetin alfa |
| gptkbp:endOfLife |
24 hours
|
| gptkbp:formulation |
Injectable solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Darbepoetin alfa
|
| gptkbp:issuedBy |
Injection
|
| gptkbp:lastProduced |
2001
|
| gptkbp:mandates |
Chronic kidney disease
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:relatedTo |
Erythropoietin
Anemia in cancer patients Anemia in renal failure Anemia of chronic disease |
| gptkbp:route |
Subcutaneous
|
| gptkbp:safetyFeatures |
Monitor hemoglobin levels
Risk of cardiovascular events Risk of stroke Risk of thrombosis |
| gptkbp:sideEffect |
Fatigue
Hypertension Nausea Headache Thromboembolic events |
| gptkbp:storage |
Refrigerated
|
| gptkbp:targets |
Cancer patients receiving chemotherapy
Patients with chronic kidney disease |
| gptkbp:triggerType |
Stimulates erythropoiesis
|
| gptkbp:usedFor |
Anemia
|
| gptkbp:weight |
37,000 Da
|